131063Occoris Inhaler Engine DevelopmentClosedFeasibility StudiesInnovate UKCurrent passive dry powder inhalers (DPIs) are limited to the treatment of asthma and COPD, and are solely reliant upon the inspiratory effort provided by the patient to create a respirable aerosol. This results in variable and inconsistent dose accuracy and prevents the possibility to treat therapies beyond asthma and COPD. The Occoris technology is a novel, active aerosolisation engine that uses a highly innovative mechanism to fluidise, aerosolise and deliver powdered drug aerosol completely independently of the inspiratory effort provided by the patient. It is simple, non electro-mechanical, low-cost and small - and offers the potential to develop inhaler products that can deliver drug in place of a needle and syringe, overcoming many of the common known issues such as needle stick, needle phobia and the transmission of infectious diseases. Possible therapy areas include: mass immunisation, pain management and diabetes.